SCHOTT Pharma Reports Strong Q2 2025 Performance

SCHOTT Pharma AG & Co. KGaA announced a substantial increase in its fiscal Q2 2025 results. Revenues rose by 8% year over year, reaching EUR 252 million, with a constant currency increase of 10%. The EBITDA margin improved to 28.6% compared to 18.9% in Q2 2024. A notable driver of this growth was the demand for high-value solutions (HVS), constituting 56% of sales.

The Drug Containment Solution segment saw a 7% growth in revenues, fueled by demand for HVS, sterile vials, and specialty vials. Meanwhile, the Drug Delivery Systems segment capitalized on strong demand for glass syringes, reporting a 9% revenue increase.

SCHOTT Pharma's focus on innovation continues, with the launch of the SCHOTT TOPPAC® freeze syringe for ultra-low temperature storage and the new 1.5 ml cartriQ® RTU cartridge. The company remains optimistic about maintaining its annual guidance amidst some macroeconomic uncertainties.